Creative Planning cut its position in shares of OHR Pharmaceutical Inc (NASDAQ:OHRP) by 32.1% in the first quarter, HoldingsChannel reports. The institutional investor owned 46,150 shares of the biotechnology company’s stock after selling 21,850 shares during the period. Creative Planning’s holdings in OHR Pharmaceutical were worth $104,000 as of its most recent SEC filing.
OHR Pharmaceutical stock opened at $2.62 on Thursday. OHR Pharmaceutical Inc has a 12-month low of $1.60 and a 12-month high of $6.60.
OHR Pharmaceutical (NASDAQ:OHRP) last released its quarterly earnings results on Thursday, February 14th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter.
About OHR Pharmaceutical
OHR Pharmaceutical, Inc operates as a development stage pharmaceutical company. The company intends to merge with NeuBase Therapeutics, Inc that focuses on advancing NeuBase's peptide-nucleic acid antisense oligonucleotide technology platform for the development of therapies to address severe and currently untreatable diseases caused by genetic mutations.
Featured Story: Asset Allocation, Balancing Your Investments
Want to see what other hedge funds are holding OHRP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OHR Pharmaceutical Inc (NASDAQ:OHRP).
Receive News & Ratings for OHR Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OHR Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.